ZJJF's subsidiary has obtained the approval notice for the listing application of fumaric acid vorinostat chemical raw materials
ZJJF's subsidiary Anhui Jianfeng Beika Pharmaceutical Co., Ltd. recently received the notice of approval for the marketing application of the chemical raw material drug Fumaric Acid Vorinostat from the National Medical Products Administration. This drug is used to treat reflux esophagitis and meets the relevant national review technical standards, marking its availability for sale in the domestic market and aiding the subsidiary's business expansion
According to the Zhitong Finance APP, ZJJF (600668.SH) announced that its subsidiary Anhui Jianfeng Beika Pharmaceutical Co., Ltd. (referred to as "Jianfeng Beika") recently received the "Approval Notice for the Application for Market Launch of Chemical Raw Material Drug Vonoprazan Fumarate" from the National Medical Products Administration (Notice No.: 2025YS00694).
Vonoprazan Fumarate is a potassium ion competitive acid blocker developed by Takeda Pharmaceutical Company Limited in Japan for the treatment of reflux esophagitis. Jianfeng Beika has the corresponding production line, and the receipt of the "Approval Notice for the Application for Market Launch of Chemical Raw Material Drug Vonoprazan Fumarate" indicates that this raw material drug has met the relevant technical standards for raw material drug review in the country and can be sold in the domestic market, which will help expand the subsidiary's business scope
